Article Figures & Data
Figures
- FIGURE 1.
Scatter plot of mean 18F-FLT SUV in pancreatic cancer with focal 18F-FLT uptake (PET-positive), in pancreatic cancer negative on visual interpretation (PET-negative), and in benign pancreatic lesions (PET-negative). MFP = mass-forming pancreatitis; PC = pancreatic cancer.
- FIGURE 2.
Spiral CT and 18F-FLT PET of patient 21, with CP, and patient 23, with pancreatic cancer. Physiologically increased 18F-FLT uptake is seen in bone marrow and liver, but only background activity of 18F-FLT is seen in area of inflammatory pancreatic mass (true-negative). Focal 18F-FLT uptake is seen in pancreatic carcinoma (true-positive).
- FIGURE 3.
Spiral CT and 18F-FLT PET of patient 18, with pancreatic cancer, and false-negative findings on 18F-FLT PET. Physiologic 18F-FLT uptake is seen in bone marrow and liver. Histology indicated T1 adenocarcinoma.
- FIGURE 4.
Receiver-operating-characteristic analysis of 18F-FLT PET for discriminating cancer from benign pancreatic lesions. Area under curve is 0.93 using cutoff of 1.8 for mean SUV or 0.92 using cutoff of 2.1 for maximal SUV.
Tables
- TABLE 1
Tumor Characteristics, Lesion Location, 18F-FLT PET Findings, Reference Method, and Clinical Consensus
Patient no. Lesion location 18F-FLT mean SUV 18F-FLT maximal SUV 18F-FLT PET visual score Reference method Clinical consensus 1 Head 3.6 4.2 1 Met, CFU 1 2 Head 1.2 1.5 0 Benign pancreatic tissue (C), CFU 0 3 Tail 3.2 3.5 1 Adenocarcinoma (H) 1 4 Head 1.6 1.8 0 Benign pancreatic tissue (C), CFU 0 5 Head 3.7 4.4 1 Adenocarcinoma (H) 1 6 Tail 2.8 3.5 1 Adenocarcinoma (H) 1 7 Head 1.7 2.0 0 Benign pancreatic tissue (H) 0 8 Head/corpus 1.4 1.7 0 Benign pancreatic tissue (H) 0 9 Head 1.4 1.6 0 Benign pancreatic tissue (C), CFU 0 10 Head 6.5 7.3 1 Squamous cell carcinoma (H) 1 11 Head 2.6 3.1 1 Adenocarcinoma (H) 1 12 Head 8.5 9.8 1 Undifferentiated adenocarcinoma (H) 1 13 Head 1.3 1.6 0 Benign pancreatic tissue (H) 0 14 Head 2.4 2.6 1 Neuroendocrine carcinoma (H) 1 15 Head 2.8 3.8 1 Adenocarcinoma (H) 1 16 Corpus 1.7 2.0 0 Adenocarcinoma (H) 1 17 Head 2.0 2.2 0 Cystadenocarcinoma (H) 1 18 Head 1.3 1.5 0 Adenocarcinoma (H) 1 19 Head 3.4 3.9 1 Adenocarcinoma (H) 1 20 Corpus 1.9 2.3 0 Adenocarcinoma (H) 1 21 Corpus 1.3 1.5 0 CFU 0 22 Head 1.4 1.6 0 Benign pancreatic tissue (H) 0 23 Head 4.9 5.1 1 Adenocarcinoma (H) 1 24 Head 1.7 1.9 0 Benign pancreatic tissue (C), CFU 0 25 Head 1.4 1.6 0 Benign pancreatic tissue (C), CFU 0 26 Corpus 2.6 3.0 1 Adenocarcinoma (H) 1 27 Head 3.0 3.4 1 Adenocarcinoma (H) 1 28 Head 2.1 4.1 1 Adenocarcinoma (H) 1 29 Head 1.7 1.9 0 Adenocarcinoma (H) 1 30 Corpus 1.4 1.6 0 Met, CFU 1 31 Head 3.6 4.2 1 Adenocarcinoma (H) 1 0 = benign; 1 = malignant; met = liver mets at MRI/CT; CFU = clinical follow-up; C = cytology; H = histology.
Nineteen of 21 malignant and 4 of 10 benign lesions were verified histologically. Cytology or clinical follow-up served as reference in remaining patients.
- TABLE 2
18F-FLT PET Findings, Using Visual Interpretation, Compared with Clinical Consensus
Clinical consensus 18F-FLT PET finding Pancreatic cancer Benign pancreatic lesion Total Negative 6 10 16 Positive 15 0 15 Total 21 10 31 Clinical consensus is based on histologic verification in 23 patients, clinical follow-up/cytologic analysis in 7 patients, and evidence of metastatic disease on CT and MRI in 1 patient. Sensitivity of 18F-FLT PET is 71%; specificity, 100%.
- TABLE 3
18F-FLT PET Findings, Using Cutoff of 1.8 for Mean SUV or 2.1 for Maximal SUV, Compared with Clinical Consensus
Clinical consensus 18F-FLT PET finding Pancreatic cancer Benign pancreatic lesion Total Negative 4 10 14 Positive 17 0 17 Total 21 10 31 Clinical consensus is based on histologic verification in 23 patients, clinical follow-up/cytologic analysis in 7 patients, and evidence of metastatic disease on CT and MRI in 1 patient. Sensitivity of 18F-FLT PET is 81%; specificity, 100%.
